Cite
HARVARD Citation
Aw, A. et al. (2017). The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & lymphoma. 58 (10), pp. 2287-2297. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Aw, A. et al. (2017). The potential combination of BCL-2 inhibitors and ibrutinib as frontline therapy in chronic lymphocytic leukemia. Leukemia & lymphoma. 58 (10), pp. 2287-2297. [Online].